iifl-logo

Zydus Lifesciences Ltd Historical Data

1,013.85
(0.19%)
Sep 5, 2025|12:00:00 AM

Invest wise with Expert advice

By continuing, I accept the T&C and agree to receive communication on Whatsapp

Zydus Lifesciences Ltd Historical Data

05/08/2025calendar-icon
05/09/2025calendar-icon
Date
Open(₹)
High(₹)
Low(₹)
Close(₹)
No. Of Trades(₹)
Total Turnover(₹)
Deliverable Quantity(₹)

07-Aug-2025

920

947.75919.05944.4532,76088,89,38,931.84,02,098

08-Aug-2025

949.8

952.05932.05936.1537,37055,53,58,7833,44,035

11-Aug-2025

940.95

958934.05955.5519,91133,70,40,724.189,676

12-Aug-2025

955.55

969948955.6538,61187,40,27,874.41,84,957

13-Aug-2025

955.65

997.5938.55988.662,0741,87,30,13,537.457,55,853

14-Aug-2025

993.55

1,002.85982.2988.828,88871,11,48,263.12,29,722

18-Aug-2025

988.8

994977.3986.543,40866,85,27,163.84,13,934

19-Aug-2025

986.5

997984.5989.4535,90971,28,47,832.64,08,101

20-Aug-2025

989.95

991.85978.35983.318,94352,63,64,969.13,19,422

21-Aug-2025

983.3

997.6978.4985.820,61170,88,32,843.53,61,654

22-Aug-2025

992

999.9986.45988.817,24730,44,74,986.369,988

25-Aug-2025

992.05

1,029.5990.91,023.1596,3812,60,60,30,089.7512,05,979

26-Aug-2025

1,015

1,016.95982987.8586,3682,96,87,57,239.414,71,641

28-Aug-2025

987.85

990.55968.4978.635,9961,08,36,53,740.056,51,350

29-Aug-2025

984.3

988.5969.2981.0528,17381,62,97,643.84,43,175

01-Sep-2025

988

998.1987991.0551,9851,45,20,83,723.89,21,753

02-Sep-2025

991.05

1,005989.7996.154,6741,10,37,63,188.15,95,183

03-Sep-2025

1,004

1,013.95999.251,008.256,6951,69,70,06,154.759,53,089

04-Sep-2025

1,014.5

1,017.41,002.51,011.9543,6831,04,64,81,8016,49,065

05-Sep-2025

1,022

1,039.051,0051,013.8557,7261,90,11,68,2014,63,340

Zydus Lifesci.: Related NEWS

Zydus Lifesciences to Seek US Approval for Saroglitazar Following Successful PBC Trial

The study, known as EPICS-III, tested the drug in adults with primary biliary cholangitis (PBC) a rare, progressive liver disease that often leaves patients with limited treatment options.

30 Aug 2025|11:24 AM
Read More
Zydus Gets Four USFDA Observations at Baddi Plant

The company said it will work with the US regulator to resolve the points raised as quickly as possible.

14 Aug 2025|11:51 AM
Read More
Zydus Wins USFDA’s Tentative Approval to Market Ibrutinib Tablets in US

This development comes after a USFDA inspection at one of Zydus' oncology facilities earlier this year.

24 Jul 2025|03:00 PM
Read More
Zydus Lifesciences’ oncology unit gets 2 USFDA observations

In its filing with the bourses, Zydus informed that these observations received were minor, and not related to data integrity.

19 Jun 2025|12:36 PM
Read More
Top Stocks for Today - 19th June 2025

Here are some of the stocks that may see significant price movement today: Jio Financial Service, Hero MotoCorp, Abbott India, etc.

19 Jun 2025|06:28 AM
Read More
Top Stocks for Today - 12th June 2025

Here are some of the stocks that may see significant price movement today: Hindustan Copper, Maruti Suzuki, Zydus Lifesciences, etc.

12 Jun 2025|06:12 AM
Read More
Zydus Lifesciences Gets Clean USFDA Nod for Ankleshwar API Facility

For Zydus, this clean report adds a layer of credibility to its US compliance track record especially since the Ankleshwar facility is a key site for its API exports.

11 Jun 2025|08:40 PM
Read More
Zydus Lifesciences Subsidiary Zynext to Acquire 5.9% Stake in Agenus for $16 Million

The acquisition is priced at $7.50 per share and will be completed in cash within 60 days, subject to regulatory approvals

3 Jun 2025|11:05 PM
Read More
Zydus Gets USFDA Fast Track Nod for ALS Drug Usnoflast

It provides benefits such as faster approval, priority review and a more open line of communication with the F.D.A.

29 May 2025|10:53 AM
Read More
Zydus Lifesciences Gets USFDA Nod for Generic Absorica to Treat Severe Acne

They are the generic form of Absorica, a well-known prescription treatment for severe and hard to treat forms of nodular acne that the patient has not responded well to other treatments with.

24 May 2025|08:15 PM
Read More

Invest wise with Expert advice

By continuing, I accept the T&C and agree to receive communication on Whatsapp

Knowledge Center
Logo

Logo IIFL Customer Care Number
(Gold/NCD/NBFC/Insurance/NPS)
1860-267-3000 / 7039-050-000

Logo IIFL Capital Services Support WhatsApp Number
+91 9892691696

Download The App Now

appapp
Loading...

Follow us on

facebooktwitterrssyoutubeinstagramlinkedintelegram

2025, IIFL Capital Services Ltd. All Rights Reserved

ATTENTION INVESTORS

RISK DISCLOSURE ON DERIVATIVES

Copyright © IIFL Capital Services Limited (Formerly known as IIFL Securities Ltd). All rights Reserved.

IIFL Capital Services Limited - Stock Broker SEBI Regn. No: INZ000164132, PMS SEBI Regn. No: INP000002213,IA SEBI Regn. No: INA000000623, SEBI RA Regn. No: INH000000248, DP SEBI Reg. No. IN-DP-185-2016, BSE Enlistment Number (RA): 5016
ARN NO : 47791 (AMFI Registered Mutual Fund Distributor)

ISO certification icon
We are ISO 27001:2013 Certified.

This Certificate Demonstrates That IIFL As An Organization Has Defined And Put In Place Best-Practice Information Security Processes.